Accuray Reports Fiscal 2022 First Quarter Financial Results
Accuray Incorporated (NASDAQ: ARAY) reported a record net revenue of $107.4 million for Q1 Fiscal 2022, a significant increase from $85.3 million year-over-year, driven by a strong 39% rise in gross orders totaling $70.0 million. However, the company faced a GAAP net loss of $1.0 million, compared to a net income of $0.4 million in the prior year. Adjusted EBITDA decreased to $5.4 million from $9.0 million. Cash reserves also fell to $105.2 million, down $11.7 million since June 2021, primarily due to bonus payouts and debt repayment.
- Record net revenue of $107.4 million for Q1 FY22, a 26% increase YoY.
- Gross orders increased by 39% to $70.0 million.
- Product revenue rose to $52.8 million from $31.3 million YoY.
- Order backlog at $602.9 million, up 1% from prior year.
- GAAP net loss of $1.0 million compared to $0.4 million profit in prior year.
- Adjusted EBITDA decreased from $9.0 million to $5.4 million YoY.
- Cash reserves decreased by $11.7 million from June 2021.
SUNNYVALE, Calif., Nov. 3, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2022 ended September 30, 2021.
First Quarter Fiscal 2022 Summary
- Record net revenue of
$107.4 million , including$25.5 million of system revenue in China, as compared to net revenue of$85.3 million in the prior period - Gross orders of
$70.0 million , an increase of 39 percent from the three months ended September 30, 2020 - GAAP Net loss of
$1.0 million as compared to GAAP Net income of$0.4 million in the prior year. Adjusted EBITDA of$5.4 million as compared to adjusted EBITDA of$9.0 million in the prior year first quarter
Other Recent Operational Highlights
- Received 510(k) clearance for VOLO™ Ultra enhancement to the Accuray Precision® treatment planning system for the Radixact® System, full commercial launch at ASTRO 2021
- Strong demand for ClearRT™ Helical kVCT Imaging for the Radixact® System: 59 global orders received since its commercial release in December 2020
- New integration with RayStation® treatment planning system for the CyberKnife® M6™ and S7™ Systems, exhibited at ASTRO 2021
"By any measure, our Q1 performance was a very strong start to our FY22 fiscal year. Q1 revenue of
Q1 Fiscal 2022 Financial Highlights
Total net revenue was
Total gross profit for the first quarter of fiscal 2022 was
Net loss was
Gross product orders totaled
Adjusted EBITDA for the first quarter of fiscal 2022 was
Cash, cash equivalents, and short-term restricted cash were
Conference Call Information
Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the first quarter of fiscal 2022 as well as recent corporate developments. Conference call dial-in information is as follows:
- U.S. callers: (833) 316-0563
- International callers: (412) 317-5747
Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the company's Investor Relations page at www.accuray.com.
In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will be available for seven days. The replay number is (877) 344-7529 (USA), or (412) 317-0088 (International), Conference ID: 10161091. An archived webcast will also be available on Accuray's website until Accuray announces its results for the second quarter of fiscal 2022.
Use of Non-GAAP Financial Measures
Accuray has supplemented its GAAP net loss with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation ("adjusted EBITDA"). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net income (loss) (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.
There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including expectations regarding total revenue and adjusted EBITDA; expectations regarding the effect of the COVID-19 pandemic on the company and the market in general; expectations regarding the company's commercial strategy and execution as well as long-term growth opportunities; expectations regarding the company's order growth; the company's ability to drive accelerated revenue growth; expectations regarding the company's China joint venture and other partnerships; expectations regarding the company's product innovations and developments; expectations regarding the company's product portfolio and its ability to position the company for growth; the impact of the company's products on its customers and its business, and market adoption of such products, including with respect to the company's VOLO Ultra enhancement and Clear RT Helical kVCT Imaging upgrades as well as other strategic product innovations; expectations regarding the future of radiotherapy treatment and the company's addressable market; and the company's leadership position in radiation oncology innovation and technologies. These forward-looking statements involve risks and uncertainties. If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the COVID-19 pandemic on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products, including new product and software offerings; the company's ability to develop new products or enhance existing products to meet customers' needs and compete favorably in the market, the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to effectively manage its growth; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 17, 2021 and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Financial Tables to Follow
Accuray Incorporated Consolidated Statements of Operations (in thousands, except per share data) (Unaudited) | ||||||||
Three Months Ended September 30, | ||||||||
2021 | 2020 | |||||||
Net revenue: | ||||||||
Products | $ | 52,759 | $ | 31,258 | ||||
Services | 54,683 | 54,074 | ||||||
Total net revenue | 107,442 | 85,332 | ||||||
Cost of revenue: | ||||||||
Cost of products | 31,509 | 18,426 | ||||||
Cost of services | 36,409 | 31,503 | ||||||
Total cost of revenue | 67,918 | 49,929 | ||||||
Gross profit | 39,524 | 35,403 | ||||||
Operating expenses: | ||||||||
Research and development | 14,382 | 12,148 | ||||||
Selling and marketing | 11,271 | 8,898 | ||||||
General and administrative | 11,460 | 8,889 | ||||||
Total operating expenses | 37,113 | 29,935 | ||||||
Income from operations | 2,411 | 5,468 | ||||||
Loss on equity investment, net | (340) | (28) | ||||||
Other expense, net | (2,668) | (4,694) | ||||||
Income (loss) before provision for income taxes | (597) | 746 | ||||||
Provision for income taxes | 431 | 344 | ||||||
Net income (loss) | $ | (1,028) | $ | 402 | ||||
Net income (loss) per share - basic | $ | (0.01) | $ | 0.00 | ||||
Net income (loss) per share - diluted | $ | (0.01) | $ | 0.00 | ||||
Weighted average common shares used in computing income (loss) per share: | ||||||||
Basic | 90,838 | 91,194 | ||||||
Diluted | 90,838 | 91,681 | ||||||
Accuray Incorporated Consolidated Balance Sheets (in thousands) (Unaudited) | ||||||||
September 30, | June 30, | |||||||
2021 | 2021 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 104,679 | $ | 116,369 | ||||
Restricted cash | 553 | 560 | ||||||
Accounts receivable, net | 94,038 | 85,360 | ||||||
Inventories | 126,493 | 125,929 | ||||||
Prepaid expenses and other current assets | 22,263 | 21,547 | ||||||
Deferred cost of revenue | 2,492 | 3,008 | ||||||
Total current assets | 350,518 | 352,773 | ||||||
Property and equipment, net | 12,263 | 12,332 | ||||||
Investment in joint venture | 14,742 | 15,935 | ||||||
Goodwill | 57,951 | 57,960 | ||||||
Intangible assets, net | 378 | 435 | ||||||
Operating lease right-of-use assets | 21,278 | 22,522 | ||||||
Other assets | 18,646 | 18,141 | ||||||
Total assets | $ | 475,776 | $ | 480,098 | ||||
Liabilities and equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 22,569 | $ | 19,467 | ||||
Accrued compensation | 20,848 | 26,865 | ||||||
Operating lease liabilities, current | 8,263 | 8,169 | ||||||
Other accrued liabilities | 31,255 | 27,471 | ||||||
Customer advances | 22,828 | 24,937 | ||||||
Deferred revenue | 78,890 | 81,660 | ||||||
Short-term debt | 3,664 | 3,790 | ||||||
Total current liabilities | 188,317 | 192,359 | ||||||
Long-term other liabilities | 7,835 | 7,766 | ||||||
Deferred revenue | 23,828 | 23,685 | ||||||
Operating lease liabilities, non-current | 15,886 | 17,441 | ||||||
Long-term debt | 194,145 | 170,007 | ||||||
Total liabilities | 430,011 | 411,258 | ||||||
Equity: | ||||||||
Common stock | 91 | 91 | ||||||
Additional paid-in capital | 531,553 | 554,680 | ||||||
Accumulated other comprehensive income | 2,324 | 2,093 | ||||||
Accumulated deficit | (488,203) | (488,024) | ||||||
Total equity | 45,765 | 68,840 | ||||||
Total liabilities and equity | $ | 475,776 | $ | 480,098 | ||||
Accuray Incorporated Summary of Orders and Backlog (in thousands) (Unaudited) | ||||||||
Three Months Ended September 30, | ||||||||
2021 | 2020 | |||||||
Gross Orders | $ | 69,984 | $ | 50,528 | ||||
Net Orders | 40,763 | 23,554 | ||||||
Order Backlog | 602,905 | 597,276 | ||||||
Accuray Incorporated Reconciliation of GAAP Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) (in thousands) (Unaudited) | ||||||||
Three Months Ended September 30, | ||||||||
2021 | 2020 | |||||||
GAAP net income (loss) | $ | (1,028) | $ | 402 | ||||
Depreciation and amortization (a) | 1,419 | 1,650 | ||||||
Stock-based compensation | 2,516 | 2,244 | ||||||
Interest expense, net (b) | 2,036 | 4,393 | ||||||
Provision for income taxes | 431 | 344 | ||||||
Adjusted EBITDA | $ | 5,374 | $ | 9,033 | ||||
(a) | consists of depreciation, primarily on property and equipment as well as amortization of intangibles. | |||||
(b) | consists primarily of interest expense associated with outstanding debt. | |||||
Joseph Diaz | Beth Kaplan |
Managing Partner, Investor Relations, Lytham Partners, LLC | Public Relations Director, Accuray |
+1 (602) 889-9660 | +1 (408) 789-4426 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-reports-fiscal-2022-first-quarter-financial-results-301415674.html
SOURCE Accuray Incorporated
FAQ
What were Accuray's earnings for Q1 Fiscal 2022?
What was the net income reported by Accuray for Q1 FY22?
How much did Accuray's gross orders increase in Q1 FY22?
What was the adjusted EBITDA for Accuray in Q1 Fiscal 2022?
What is Accuray's stock symbol?
